Zoetis Inc. (ZTS) Holdings Reduced by Sciencast Management LP
Sciencast Management LP trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 27.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,541 shares of the company’s stock after selling 6,148 shares during the period. Sciencast Management LP’s holdings in Zoetis were worth $1,032,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. boosted its stake in Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the last quarter. Guardian Life Insurance Co. of America boosted its stake in Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after purchasing an additional 13 shares during the last quarter. Point72 Asia Hong Kong Ltd purchased a new stake in Zoetis during the 1st quarter valued at $111,000. Harfst & Associates Inc. boosted its stake in Zoetis by 16.1% during the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares during the last quarter. Finally, Almanack Investment Partners LLC. purchased a new stake in Zoetis during the 2nd quarter valued at $119,000. Institutional investors and hedge funds own 93.20% of the company’s stock.
ZTS has been the topic of several recent analyst reports. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Hilliard Lyons initiated coverage on Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 target price on the stock. Deutsche Bank AG reiterated a “buy” rating and set a $65.00 target price (up from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 target price on shares of Zoetis in a research note on Friday, July 21st. Finally, Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the company a “buy” rating in a research note on Monday, August 14th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $65.44.
Zoetis Inc. (NYSE:ZTS) traded up 0.055% during midday trading on Friday, reaching $63.785. The company’s stock had a trading volume of 1,147,612 shares. The stock’s 50 day moving average price is $63.33 and its 200-day moving average price is $60.42. The stock has a market cap of $31.20 billion, a price-to-earnings ratio of 36.057 and a beta of 1.02. Zoetis Inc. has a one year low of $46.86 and a one year high of $65.83.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.53. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.49 earnings per share. On average, analysts forecast that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be given a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a dividend yield of 0.66%. Zoetis’s dividend payout ratio (DPR) is presently 23.73%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.